MedTrace Logo

Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022

NCT06930989 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 148467

Last updated 2025-05-23

No results posted yet for this study

Summary

Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibrillation, ischemic heart disease, heart failure and stroke. OSA is also an independent promoter of hypertension development and poorly controlled hypertension is overrepresented in OSA. Finally, HT and OSA share many risk factors including obesity, and several lifestyle factors. Altogether, these links contribute to a high prevalence of patients with both disorders.

The investigators suspect participants with HT and OSA are at even higher CV risk and may get their first CV event earlier in life. Comparison between HT and OSA participants vs HT alone, OSA alone or healthy controls has not previously been investigated in large studies.

Thus, the investigators aim to investigate long-term risk of major cardiovascular events (MACE) or death comparing these groups in registry data between 2010-2022 in Sweden. The investigators will also investigate the protecting effect of positive airway pressure (PAP) on the OSA related CV risk increase and how many hours/night of PAP use is needed to get any protective effects.

Conditions

  • Hypertension
  • OSA - Obstructive Sleep Apnea
  • MACE
  • Survival Analysis
  • PAP

Interventions

DEVICE

Positive airway pressure (PAP)

Intervention as part of routine clinical care. Data from national registries.

Sponsors & Collaborators

  • Swedish Heart Lung Foundation

    collaborator OTHER

  • Göteborg University

    collaborator OTHER

  • Lund University

    collaborator OTHER

  • Uppsala University

    collaborator OTHER

  • Vastra Gotaland Region

    lead OTHER_GOV

Principal Investigators

  • Sven Svedmyr, MD · Sahlgrenska University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-04-08
Completion
2025-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06930989 on ClinicalTrials.gov